April 24, 2018
RxAnte President and CEO Josh Benner took the podium at the AMCP Annual Meeting in Boston today, speaking on how leveraging real-world evidence (RWE) is critical to move the market forward in value-based contracting (VBC).
In today’s value-focused healthcare environment, health plans and pharmaceutical manufacturers have a shared interest in getting more value from medicines, but there are still significant barriers to accelerated market growth in the VBC space:
For health plans, this includes a lack of resources and technology infrastructure to manage a new contracting approach such as VBC, along with a need for clearer line of sight into how their member populations will fare on specific therapies from a health outcomes perspective. Pharmaceutical manufacturers are challenged by the need for additional personnel and infrastructure to manage multiple VBCs concurrently, a limited ability to improve performance at the member level, and the need for VBC outcomes to remain focused on what is on the product’s label and born out in clinical trials.
The talk featured a case study on RxAnte’s work with UPMC Health Plan, where RxAnte facilitated the collection and analysis of RWE in order to inform how VBCs should be designed and executed. Stay tuned for a recap of our week at AMCP, featuring key takeaways from our discussion on value-based contracting.
Contact us today or stop by booth #713 at AMCP to learn more about how RxAnte is helping health plans and manufacturers collaborate on RWE work to inform both quality improvement programs and value-based contracts.